CN102740693A - 用于治疗与神经激肽2受体活性相关的病症或疾病的化合物 - Google Patents

用于治疗与神经激肽2受体活性相关的病症或疾病的化合物 Download PDF

Info

Publication number
CN102740693A
CN102740693A CN2010800501768A CN201080050176A CN102740693A CN 102740693 A CN102740693 A CN 102740693A CN 2010800501768 A CN2010800501768 A CN 2010800501768A CN 201080050176 A CN201080050176 A CN 201080050176A CN 102740693 A CN102740693 A CN 102740693A
Authority
CN
China
Prior art keywords
compound
disorder
pharmaceutically acceptable
subject
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800501768A
Other languages
English (en)
Chinese (zh)
Inventor
J·拜恩
J·萨达维
H·陈
X·沈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Paragon Assoc Inc
Original Assignee
United Paragon Assoc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Paragon Assoc Inc filed Critical United Paragon Assoc Inc
Publication of CN102740693A publication Critical patent/CN102740693A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/30—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with trihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/003—Esters of saturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN2010800501768A 2009-09-04 2010-09-07 用于治疗与神经激肽2受体活性相关的病症或疾病的化合物 Pending CN102740693A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24001409P 2009-09-04 2009-09-04
US61/240,014 2009-09-04
PCT/US2010/048006 WO2011029099A1 (en) 2009-09-04 2010-09-07 Compounds for treating disorders or diseases associated with neurokinin 2 receptor activity

Publications (1)

Publication Number Publication Date
CN102740693A true CN102740693A (zh) 2012-10-17

Family

ID=43649685

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800501768A Pending CN102740693A (zh) 2009-09-04 2010-09-07 用于治疗与神经激肽2受体活性相关的病症或疾病的化合物

Country Status (14)

Country Link
US (1) US20120190743A1 (enExample)
EP (1) EP2473038A4 (enExample)
JP (1) JP2013503908A (enExample)
KR (1) KR20120081120A (enExample)
CN (1) CN102740693A (enExample)
AU (1) AU2010289276A1 (enExample)
BR (1) BR112012004988A2 (enExample)
CA (1) CA2773035A1 (enExample)
MX (1) MX2012002551A (enExample)
NZ (1) NZ599215A (enExample)
RU (1) RU2012112943A (enExample)
SG (1) SG178964A1 (enExample)
WO (1) WO2011029099A1 (enExample)
ZA (1) ZA201202492B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2508180A1 (en) 2011-04-04 2012-10-10 Nestec S.A. Sn-1(3) Monoacylglycerides and lipid absorption
WO2015017575A2 (en) 2013-08-01 2015-02-05 Dignify Therapeutics, Inc. Compositions and methods for inducing urinary voiding and defecation
GB201315846D0 (en) 2013-09-05 2013-10-23 Imp Innovations Ltd Method for treating or preventing hot flushes

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070254904A1 (en) * 2004-04-06 2007-11-01 Janssen Pharmaceutica N.V. Substituted Diaza-Spiro-[4.5]-Decane Derivatives and Their Use as Neurokinin Antagonists
US20080089836A1 (en) * 2006-10-12 2008-04-17 Nanoprobes, Inc. Functional associative coatings for nanoparticles
US7410970B2 (en) * 2002-10-08 2008-08-12 Janssen Pharmaceutica, N.V. Substituted 1,4,-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists
WO2009086634A1 (en) * 2008-01-11 2009-07-16 United Paragon Associates Inc. Fertilized egg isolate and use thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1001A (en) * 1838-11-09 Open grate fobj burning coai
GB820954A (en) * 1956-05-02 1959-09-30 Beecham Res Lab Improvements in or relating to esters of 2,3-dimercaptopropanol
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS505309A (enExample) * 1973-05-28 1975-01-21
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
JPH02131418A (ja) * 1988-11-10 1990-05-21 Sansho Seiyaku Co Ltd 外用剤
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
DE4204151A1 (de) * 1992-02-12 1993-08-19 Schneider Manfred Prof Dr Regioisomerenreine monoglyceride sowie ein verfahren zu ihrer herstellung durch enzymatische veresterung von glycerin in organischen loesungsmitteln
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
JPH0931020A (ja) * 1995-07-25 1997-02-04 Soda Koryo Kk グリセロールモノ−６−ヒドロキシアルカン酸エステル、及びこれを含有する香料組成物
SE9604582D0 (sv) * 1996-12-13 1996-12-13 Astra Ab Novel compounds
CN100528829C (zh) * 1999-11-18 2009-08-19 R·L·佩德森 信息素或其成分的复分解合成
CN1286529C (zh) * 2004-06-11 2006-11-29 华中科技大学 具有皮肤靶向性的药物组合物及其制备方法和用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7410970B2 (en) * 2002-10-08 2008-08-12 Janssen Pharmaceutica, N.V. Substituted 1,4,-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists
US20070254904A1 (en) * 2004-04-06 2007-11-01 Janssen Pharmaceutica N.V. Substituted Diaza-Spiro-[4.5]-Decane Derivatives and Their Use as Neurokinin Antagonists
US20080089836A1 (en) * 2006-10-12 2008-04-17 Nanoprobes, Inc. Functional associative coatings for nanoparticles
WO2009086634A1 (en) * 2008-01-11 2009-07-16 United Paragon Associates Inc. Fertilized egg isolate and use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRIDGETT E. COLEMAN ET AL.: "Modular Approach to the Synthesis of Unsaturated 1-Monoacyl Glycerols", 《SYNLETT》, no. 8, 18 May 2004 (2004-05-18), pages 1339 - 1342, XP055078803, DOI: doi:10.1055/s-2004-825616 *
DANIEL I. BATOVSKA ET AL.: "Antibacterial Study of the Medium Chain Fatty Acids and Their 1-Monoglycerides Individual Effects and Synergistic Relationship", 《POLISH JOURNAL OF MICROBIOLOGY》, vol. 58, no. 1, 31 March 2009 (2009-03-31), pages 43 - 47 *

Also Published As

Publication number Publication date
ZA201202492B (en) 2013-02-27
RU2012112943A (ru) 2013-10-10
JP2013503908A (ja) 2013-02-04
EP2473038A4 (en) 2013-10-23
NZ599215A (en) 2014-11-28
CA2773035A1 (en) 2011-03-10
MX2012002551A (es) 2012-09-07
WO2011029099A1 (en) 2011-03-10
AU2010289276A1 (en) 2012-05-03
BR112012004988A2 (pt) 2015-09-08
KR20120081120A (ko) 2012-07-18
EP2473038A1 (en) 2012-07-11
US20120190743A1 (en) 2012-07-26
SG178964A1 (en) 2012-04-27

Similar Documents

Publication Publication Date Title
KR101739800B1 (ko) 안드로겐 수용체 조절제의 에스터 유도체 및 그의 이용 방법
TWI765995B (zh) 雙環雜芳基衍生物及其製備與用途
MX2014014234A (es) Benzamidas n-sustituidas y su uso en el tratamiento del dolor.
TW201440812A (zh) 作為免疫調節劑及抗癌劑的雷公藤內酯醇化合物之靜脈內調配物
JP2016530285A (ja) 癌の撮像及び治療のためのハロゲン化化合物、及びその使用方法
CN113880766A (zh) 一种免疫调节剂
EP3210969A1 (en) Kcnq2-5 channel activator
JP7744689B2 (ja) 脂質代謝関連疾患の予防又は治療用化合物
WO2020076815A1 (en) Steroid compounds as treg modulators and uses thereof
JP2017081957A (ja) 化合物
CN109071456A (zh) 作为myc调节剂的max结合剂及其用途
WO2023081895A1 (en) Isotopically enriched analogs of 5,6-methylenedioxy-2-aminoindane (mdai)
CN102740693A (zh) 用于治疗与神经激肽2受体活性相关的病症或疾病的化合物
JP2016508489A (ja) プロトパナキサジオール誘導体、その製造方法及びその応用
WO2014134202A1 (en) Cancer therapy
EP3447045B9 (en) 1-(1-hydroxy-2,3-dihydro-1h-inden-5-yl)-urea derivatives and related compounds kcnq 2-5 channel activators for treating dysuria
CN115477611B (zh) 用于治疗假性变态反应的mrgprx2拮抗剂
JPWO2005079845A1 (ja) 片頭痛予防薬
HK1177391A (en) Compounds for treating disorders or diseases associated with neurokinin 2 receptor activity
JP2016516089A (ja) ５−ｈｔ４受容体アゴニストとしての５−アミノ−キノリン−８−カルボキサミド誘導体
CN1678300A (zh) 可用于治疗慢性髓细胞性白血病的药物组合物
JP2025530203A (ja) うつ病を処置するための方法
CA3132179A1 (en) Method of inhibiting trem-1
WO2025122714A1 (en) Haloperidol derivatives, pharmaceutical composition comprising said derivatives, and therapeutic use thereof
TWI535725B (zh) 用以治療發炎和／或腫瘤的新穎倍半萜類化合物之衍生物及包含此新穎倍半萜類化合物之衍生物的組合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1177391

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121017